¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer.

Date publication

février 2016

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr COCHET Alexandre

Tous les auteurs :
Groheux D, Cochet A, Humbert O, Alberini JL, Hindié E, Mankoff D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26834096

Résumé

Many studies have pointed out the role of (18)F-FDG PET/CT (or (18)F-FDG PET) in patients with clinical stage III or II breast cancer. (18)F-FDG PET/CT might advantageously replace other staging procedures, such as bone scanning and possibly contrast-enhanced CT of the thorax or abdomen-pelvis. We discuss the findings, locoregional or distant, that can be expected in different categories of breast cancer and their impact on prognosis and management. We also discuss the role of (18)F-FDG PET/CT in restaging and how (18)F-FDG PET/CT compares with conventional techniques in restaging for patients with suspected disease recurrence. We conclude with some recommendations for clinical practice and future research.

Mots clés

Breast Neoplasms, diagnostic imaging, Female, Fluorodeoxyglucose F18, Humans, Multimodal Imaging, Neoplasm Staging, methods, Positron-Emission Tomography, methods, Prognosis, Radiopharmaceuticals, Tomography, X-Ray Computed

Référence

J. Nucl. Med.. 2016 Feb;57 Suppl 1:17S-26S